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Introduction
Prophylactic implantation of a cardioverter/defibrillator
(ICD) has been shown to reduce mortality in patients
with chronic myocardial infarction (CMI) and an
increased risk for life threatening ventricular arrhythmia
(VA). VA is related to infarct size and seems to be related
to infarct morphology. Contrast enhanced cardiovascular
magnetic resonance imaging (ceCMR) can detect and
quantify myocardial fibrosis in the setting of CMI and
might therefore be a valuable tool for more accurate risk
stratification in this setting.
Purpose
ceCMR can identify the subgroup developing VA in
patients with prophylactic ICD implantation following
MADIT criteria.
Methods
We prospectively enrolled 50 patients (47 males, age 68 ±
10 years) with CMI and clinical indication for ICD ther-
apy following MADIT criteria. Prior to implantation (28 ±
72 days) patients were investigated on a 1.5 T clinical
scanner to assess left ventricular function (LVEF) and late
hyperenhancement for quantitative assessment of infarct
morphology including total infarct mass, infarct mass
related to LV mass, and the degree of transmurality
defined by transmural to non-transmural extent in each
scar (sequence: inversion recovery gradient echo; matrix
256 × 148, imaging 10–30 min after 0.2 μg/kg gadolin-
ium DTPA; short axis stack; full coverage of the LV, no gap;
slice thickness 6 mm). After implantation, patients were
followed up including ICD readout after 3 and than every
6 months for a mean of 692 ± 292 days. ICD data were
evaluated by an experienced electrophysiologist. Primary
endpoint was the occurrence of an appropriate discharge
(DC), antitachycard pacing (ATP) or death from cardiac
cause.
Results
The endpoint occurred in 9 cases (5 DC, 3 ATP, 1 death).
There was no significant association between the end-
point and LVEF (31 ± 9 vs. 31 ± 11, p = 0.97), total infarct
mass (50 ± 19 vs 53 ± 34 g, p = 0.78) or infarct size related
to left ventricular mass (29 ± 6% vs. 30 ± 16, p = 0.87).
The degree of transmurality was significantly associated
with the occurrence of the endpoint. Scars with mainly
transmural (> 75%) or strictly subendocardial extent (<
50%) were less likely to show ventricular arrhythmia than
scars with a transmural extent of 50–75% (Chi-Square p =
0.035).
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In patients fulfilling MADIT criteria ceCMR could identify
a subgroup at higher risk for VA. These preliminary results
support the hypothesis that patients with large infarcts of
mainly non-transmural extent are at increased risk for VA.
Larger trials are needed to confirm this finding.Page 2 of 2
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